Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

April 20, 2021

Martell Diagnostic Laboratories, Inc. has announced the launch of its new diagnostic test for breast cancer patients – HERTEST.

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors. HERTEST uses state-of-the-art antibodies to detect HER2 at diagnosis, as well as uncovering HER2 tumors in women with primary tumors originally testing negative at diagnosis. HERTEST is available both as a  traditional lab test and as a lateral flow assay. The traditional lab test is available in the United States and the lateral flow assay will be made available for use in developing countries where lab testing is not available.

“We’re tremendously excited to give women and their oncologists all over the world a better way to guide cancer therapy,” said Michelle Edwards, CEO of Martell Diagnostics Laboratories. “HERTEST can help deliver on the promise of targeted therapy for millions of women.”

Michelle Edwards, new CEO of Martell Diagnostic Laboratories, leads the Minnesota-based team with a primary goal of offering their flagship test, HERTEST, to the masses for improved onco-therapeutics and drug efficacy for breast cancer patients that will reduce costs and drug-use. HERTEST is currently in clinical trials and partnership with the University of Minnesota, Mayo Clinic, and Kilimanjaro Cancer Center in Tanzania, with planned expansion to Bangladesh and Honduras.

In the U.S., 300,000 women are diagnosed with breast cancer each year with HER2 breast cancer making up about 20% of those cases. Globally, over 2.3 million new breast cancer diagnoses are delivered annually, with even higher rates of HER2 positivity.  HERTEST will help answer breast cancer patients’ questions and give physicians specific, real time data regarding patient status and better treatment options.

Targeted therapy in breast cancer treatments traditionally requires hefty costs and limitations leading oncologists to seek new tests that will lower drug use and increase quality of life. Currently, women wait 10-14 days to receive results about the progression of their condition, losing valuable time in treatment. With more than 100 peer-reviewed articles supporting the importance of HER2 testing for treatment, HERTEST monitoring provides useful information to support cancer treatment de-escalation within two days of the test.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.